Setting the cytokine trap for autoimmunity.
Dinarello
Charles A
CA
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D001665:Binding Sites; D017322:Clinical Trials, Phase II as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000628:therapy; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D011485:Protein Binding; D016032:Randomized Controlled Trials as Topic; D018121:Receptors, Cytokine / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D017472:Receptors, Interleukin-1 / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism
D016207:Cytokines; D007375:Interleukin-1; D018121:Receptors, Cytokine; D017472:Receptors, Interleukin-1; D014409:Tumor Necrosis Factor-alpha